Athenex, Inc.: directors' dealings · United States · SEC (Form 4)

About Athenex, Inc.

Athenex, Inc. (ticker: ATNX) was a U.S.-listed biopharmaceutical company whose common stock traded on the Nasdaq Global Select Market, making it a NYSE/NASDAQ-style U.S. public-market name for investors following SEC disclosures and insider activity. The company was historically headquartered in Buffalo, New York, United States. It was formed in November 2003 as Kinex Pharmaceuticals LLC, began operations in February 2004, and later converted into a Delaware corporation in December 2012 before taking the Athenex name. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000095017023008734/atnx-20221231.htm?utm_source=openai)) From a business-model standpoint, Athenex was built as an oncology-focused biotech with a mix of research, development, manufacturing, and specialty commercialization. Its core scientific narrative centered on oral taxane delivery through the Orascovery platform, including oral paclitaxel and encequidar, alongside other technology platforms such as Src kinase inhibition, TCR-T cell therapy, and arginine deprivation approaches. The company’s historical pipeline also included candidates such as KX-01 and KX-02. In addition to clinical-stage development, Athenex operated commercial channels through Athenex Pharmaceutical Division (APD) and 503B compounding-related activities through Athenex Pharma Solutions (APS). ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000119312519313488/d838422dex991.htm?utm_source=openai)) Geographically, Athenex had a comparatively broad footprint for a mid-cap biotech, with U.S. offices and facilities in Buffalo, Clarence, Cranford, Houston, and Chicago, plus operations or offices in Hong Kong, Taipei, multiple locations in Chongqing, Manchester, Guatemala City, and Buenos Aires. That international setup supported clinical development, manufacturing, and commercial execution, but it also underscored the complexity of the organization. In competitive terms, Athenex operated in a crowded global oncology market where capital access, regulatory milestones, and trial outcomes are critical differentiators. Its positioning depended less on scale and more on whether its technology could generate clinically meaningful and approvable products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000119312519313488/d838422dex991.htm?utm_source=openai)) Recent SEC disclosures and filings show a company that had entered a difficult strategic and financial phase, with management focusing on preserving and advancing the remaining platform assets while operating under heightened uncertainty. For investors, especially French, Belgian, and Swiss readers screening Form 4 insider transactions, Athenex should be viewed as a high-risk biotech case study rather than a mature commercial pharmaceutical platform. The investment thesis historically hinged on pipeline execution, regulatory progress, and the ability to convert scientific promise into durable commercial value. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000095017023008734/atnx-20221231.htm?utm_source=openai))